| P50 | author | Louis H. Miller | Q1646045 |
| | Michael Theisen | Q58310143 |
| | Toshihiro Horii | Q62911332 |
| | Sumi Biswas | Q91598971 |
| | Evelina Angov | Q107291505 |
| | Simon J. Draper | Q47576805 |
| P2093 | author name string | Prakash Srinivasan | |
| P2860 | cites work | Cloning and expression of the gene coding for the transmission blocking target antigen Pfs48/45 of Plasmodium falciparum | Q48103837 |
| | Optimising the Drosophila S2 Expression System for Production of Therapeutic Vaccines | Q56144357 |
| | Plasmodium falciparum apical membrane antigen 1 (PfAMA-1) is translocated within micronemes along subpellicular microtubules during merozoite development | Q73764830 |
| | Vaccines against malaria | Q17485685 |
| | The cellular and molecular basis for malaria parasite invasion of the human red blood cell | Q21032502 |
| | A review of malaria vaccine clinical projects based on the WHO rainbow table | Q21034112 |
| | Algae-produced Pfs25 elicits antibodies that inhibit malaria transmission | Q21134576 |
| | Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies | Q24289322 |
| | Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum | Q24297064 |
| | Multiprotein complex between the GPI-anchored CyRPA with PfRH5 and PfRipr is crucial for Plasmodium falciparum erythrocyte invasion | Q27230042 |
| | Vaccination with Plasmodium knowlesi AMA1 formulated in the novel adjuvant co-vaccine HT™ protects against blood-stage challenge in rhesus macaques | Q27336448 |
| | Structure of the Malaria Antigen AMA1 in Complex with a Growth-Inhibitory Antibody | Q27648686 |
| | Host cell invasion by apicomplexan parasites: insights from the co-structure of AMA1 with a RON2 peptide | Q27670931 |
| | Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus | Q27680499 |
| | Independent roles of apical membrane antigen 1 and rhoptry neck proteins during host cell invasion by apicomplexa | Q27972557 |
| | Apical membrane antigen 1 mediates apicomplexan parasite attachment but is dispensable for host cell invasion | Q27973517 |
| | A field trial to assess a blood-stage malaria vaccine | Q35622737 |
| | Ad35.CS.01-RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults | Q35684141 |
| | Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates | Q35813430 |
| | Update on the clinical development of candidate malaria vaccines. | Q35872686 |
| | Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich pro | Q36227049 |
| | Evidence for a common role for the serine-type Plasmodium falciparum serine repeat antigen proteases: implications for vaccine and drug design | Q36313967 |
| | Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge | Q36313990 |
| | Antimalarial immunity in Saimiri monkeys. Immunization with surface components of asexual blood stages | Q36349409 |
| | Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito | Q36351262 |
| | Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines | Q36362230 |
| | Proteolytic activation of the essential parasitophorous vacuole cysteine protease SERA6 accompanies malaria parasite egress from its host erythrocyte | Q36368252 |
| | Enhancing blockade of Plasmodium falciparum erythrocyte invasion: assessing combinations of antibodies against PfRH5 and other merozoite antigens | Q36384456 |
| | Humoral responses to plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa. | Q36421572 |
| | ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans | Q36460499 |
| | A full-length recombinant Plasmodium falciparum PfRH5 protein induces inhibitory antibodies that are effective across common PfRH5 genetic variants | Q36511421 |
| | Anti-Plasmodium falciparum invasion ligand antibodies in a low malaria transmission region, Loreto, Peru | Q36531268 |
| | Wheat germ cell-free system-based production of malaria proteins for discovery of novel vaccine candidates | Q36539678 |
| | NF135.C10: a new Plasmodium falciparum clone for controlled human malaria infections | Q36547334 |
| | Iron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood-stage human malaria vaccine | Q36615170 |
| | Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01. | Q36639261 |
| | Correctly folded Pfs48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in mice | Q36670217 |
| | Various PfRH5 polymorphisms can support Plasmodium falciparum invasion into the erythrocytes of owl monkeys and rats | Q36678022 |
| | Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses | Q36693991 |
| | A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits | Q36710710 |
| | The oligomerization domain of C4-binding protein (C4bp) acts as an adjuvant, and the fusion protein comprised of the 19-kilodalton merozoite surface protein 1 fused with the murine C4bp domain protects mice against malaria. | Q36804322 |
| | Overcoming allelic specificity by immunization with five allelic forms of Plasmodium falciparum apical membrane antigen 1. | Q36826951 |
| | Diversity covering AMA1-MSP119 fusion proteins as malaria vaccines | Q36826984 |
| | Comparison of modeling methods to determine liver-to-blood inocula and parasite multiplication rates during controlled human malaria infection | Q36936348 |
| | Alga-produced cholera toxin-Pfs25 fusion proteins as oral vaccines | Q36970645 |
| | Apical membrane antigen 1: a malaria vaccine candidate in review | Q37069649 |
| | Erythrocyte binding protein PfRH5 polymorphisms determine species-specific pathways of Plasmodium falciparum invasion | Q37181802 |
| | Immunity to malaria: more questions than answers | Q37194482 |
| | Plasmodium falciparum merozoite surface antigen, PfRH5, elicits detectable levels of invasion-inhibiting antibodies in humans | Q37247459 |
| | A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites | Q27973519 |
| | A subset of Plasmodium falciparum SERA genes are expressed and appear to play an important role in the erythrocytic cycle | Q27974188 |
| | The RTS,S malaria vaccine | Q28285472 |
| | Inhibitory potential of prodomain of Plasmodium falciparum protease serine repeat antigen 5 for asexual blood stages of parasite | Q28479056 |
| | Immunogenicity of self-associated aggregates and chemically cross-linked conjugates of the 42 kDa Plasmodium falciparum merozoite surface protein-1 | Q28484081 |
| | The RON2-AMA1 interaction is a critical step in moving junction-dependent invasion by apicomplexan parasites | Q28742887 |
| | A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide® ISA 720 | Q28744696 |
| | Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults | Q28749215 |
| | Immunization with Pre-Erythrocytic Antigen CelTOS from Plasmodium falciparum Elicits Cross-Species Protection against Heterologous Challenge with Plasmodium berghei | Q28749621 |
| | High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model | Q28749979 |
| | Monoclonal antibody characterization of Plasmodium falciparum antigens in immune complexes formed when schizonts rupture in the presence of immune serum | Q30042480 |
| | An EGF-like protein forms a complex with PfRh5 and is required for invasion of human erythrocytes by Plasmodium falciparum | Q30043132 |
| | Subcellular discharge of a serine protease mediates release of invasive malaria parasites from host erythrocytes | Q30043441 |
| | CelTOS, a novel malarial protein that mediates transmission to mosquito and vertebrate hosts | Q30045410 |
| | Passive immunoprotection of Plasmodium falciparum-infected mice designates the CyRPA as candidate malaria vaccine antigen | Q30049113 |
| | PfRH5: a novel reticulocyte-binding family homolog of plasmodium falciparum that binds to the erythrocyte, and an investigation of its receptor | Q30049204 |
| | RH5-Basigin interaction plays a major role in the host tropism of Plasmodium falciparum. | Q30356310 |
| | Protective epitopes of the Plasmodium falciparum SERA5 malaria vaccine reside in intrinsically unstructured N-terminal repetitive sequences. | Q30363119 |
| | Binding of Plasmodium merozoite proteins RON2 and AMA1 triggers commitment to invasion | Q30503482 |
| | Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data | Q30814677 |
| | Identification of a major B-cell epitope of the Plasmodium falciparum glutamate-rich protein (GLURP), targeted by human antibodies mediating parasite killing | Q30897109 |
| | Analysis of the Plasmodium and Anopheles transcriptomes during oocyst differentiation | Q31027392 |
| | A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies | Q33198902 |
| | A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers | Q33302116 |
| | Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. | Q33305467 |
| | Identification of proteases that regulate erythrocyte rupture by the malaria parasite Plasmodium falciparum | Q33317962 |
| | Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. | Q33350210 |
| | An inhibitory antibody blocks interactions between components of the malarial invasion machinery | Q33402457 |
| | Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya | Q33415066 |
| | Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. | Q33434412 |
| | A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli | Q33485233 |
| | Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children | Q33512533 |
| | A bicomponent Plasmodium falciparum investigational vaccine composed of protein-peptide conjugates. | Q33524699 |
| | Global identification of multiple substrates for Plasmodium falciparum SUB1, an essential malarial processing protease | Q34739743 |
| | Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine candidate BK-SE36. | Q34749432 |
| | Optimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe | Q34792326 |
| | A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys | Q34978590 |
| | A library of functional recombinant cell-surface and secreted P. falciparum merozoite proteins | Q34991300 |
| | Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in malian children: 24-month follow-up of a randomized, double-blinded phase 2 trial | Q35048336 |
| | Overcoming antigenic diversity by enhancing the immunogenicity of conserved epitopes on the malaria vaccine candidate apical membrane antigen-1. | Q35079832 |
| | Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex | Q35132063 |
| | Crystal structure of PfRh5, an essential P. falciparum ligand for invasion of human erythrocytes | Q35167000 |
| | New antigens for a multicomponent blood-stage malaria vaccine | Q35216634 |
| | A malaria vaccine candidate based on an epitope of the Plasmodium falciparum RH5 protein | Q35227478 |
| | Development of cultured Plasmodium falciparum blood-stage malaria cell banks for early phase in vivo clinical trial assessment of anti-malaria drugs and vaccines | Q35354508 |
| | Blood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodies | Q35456892 |
| | Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25. | Q35575993 |
| | Naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs48/45 and Pfs230 in an area of seasonal transmission | Q35598030 |
| | Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay | Q37256085 |
| | A chimeric Plasmodium falciparum merozoite surface protein vaccine induces high titers of parasite growth inhibitory antibodies | Q37264673 |
| | Inducing humoral and cellular responses to multiple sporozoite and liver-stage malaria antigens using exogenous plasmid DNA. | Q37264722 |
| | TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models | Q37384724 |
| | Neutralization of Plasmodium falciparum merozoites by antibodies against PfRH5. | Q37412559 |
| | Experimentally induced blood-stage Plasmodium vivax infection in healthy volunteers. | Q37463375 |
| | A novel malaria vaccine candidate antigen expressed in Tetrahymena thermophila. | Q37529646 |
| | Challenges of assessing the clinical efficacy of asexual blood-stage Plasmodium falciparum malaria vaccines | Q37530299 |
| | Bacterially expressed full-length recombinant Plasmodium falciparum RH5 protein binds erythrocytes and elicits potent strain-transcending parasite-neutralizing antibodies | Q37548216 |
| | Naturally acquired antibodies specific for Plasmodium falciparum reticulocyte-binding protein homologue 5 inhibit parasite growth and predict protection from malaria | Q37582331 |
| | The development of the RTS,S malaria vaccine candidate: challenges and lessons | Q37582422 |
| | Adjuvants for malaria vaccines | Q37582428 |
| | From the circumsporozoite protein to the RTS, S/AS candidate vaccine | Q37608882 |
| | Potent malaria transmission-blocking antibody responses elicited by Plasmodium falciparum Pfs25 expressed in Escherichia coli after successful protein refolding | Q37713285 |
| | Blood-stage malaria vaccines - recent progress and future challenges | Q37761208 |
| | Plasmodium falciparum serine repeat antigen 5 (SE36) as a malaria vaccine candidate | Q37896256 |
| | Controlled human blood stage malaria infection: current status and potential applications | Q38001604 |
| | Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets | Q38096489 |
| | Phenotype and functions of memory Tfh cells in human blood | Q38226748 |
| | Insights and controversies into the role of the key apicomplexan invasion ligand, Apical Membrane Antigen 1. | Q38243368 |
| | T follicular helper cell differentiation, function, and roles in disease | Q38264816 |
| | Toward the development of effective transmission-blocking vaccines for malaria | Q38322553 |
| | Serine repeat antigen (SERA5) is predominantly expressed among the SERA multigene family of Plasmodium falciparum, and the acquired antibody titers correlate with serum inhibition of the parasite growth | Q38884020 |
| | Transmission-blocking effects of sera from malaria-exposed individuals on Plasmodium falciparum isolates from gametocyte carriers | Q38977787 |
| | Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate | Q38995083 |
| | Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults | Q39172614 |
| | A Plasmodium falciparum 48/45 single epitope R0.6C subunit protein elicits high levels of transmission blocking antibodies | Q39467691 |
| | Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal | Q39515540 |
| | A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages | Q39520295 |
| | The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro | Q39569469 |
| | Alanine mutagenesis of the primary antigenic escape residue cluster, c1, of apical membrane antigen 1. | Q39924371 |
| | Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children | Q40551098 |
| | Plasmodium falciparum: heterologous synthesis of the transmission-blocking vaccine candidate Pfs48/45 in recombinant vaccinia virus-infected cells | Q41003251 |
| | Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambaréné, Gabon | Q41877888 |
| | Heterologous expression of the C-terminal antigenic domain of the malaria vaccine candidate Pfs48/45 in the green algae Chlamydomonas reinhardtii | Q43645737 |
| | Malaria vaccine technology roadmap | Q43650366 |
| | Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa | Q43932881 |
| | The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis | Q33526349 |
| | Plasmodium falciparum merozoite surface protein 1 (MSP-1)-MSP-3 chimeric protein: immunogenicity determined with human-compatible adjuvants and induction of protective immune response | Q33613937 |
| | Association of antibodies to Plasmodium falciparum reticulocyte binding protein homolog 5 with protection from clinical malaria | Q33820897 |
| | Clues to evolution of the SERA multigene family in 18 Plasmodium species | Q33851402 |
| | Immunization of Saimiri sciureus monkeys with a recombinant hybrid protein derived from the Plasmodium falciparum antigen glutamate-rich protein and merozoite surface protein 3 can induce partial protection with Freund and Montanide ISA720 adjuvants | Q33858812 |
| | The Plasmodium serine-type SERA proteases display distinct expression patterns and non-essential in vivo roles during life cycle progression of the malaria parasite | Q33885507 |
| | The IC(50) of anti-Pfs25 antibody in membrane-feeding assay varies among species | Q33892507 |
| | Immunization with a functional protein complex required for erythrocyte invasion protects against lethal malaria | Q33925720 |
| | Structure of AMA1 from Plasmodium falciparum reveals a clustering of polymorphisms that surround a conserved hydrophobic pocket | Q33943794 |
| | Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909. | Q33974904 |
| | A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children | Q33987686 |
| | Specificity of the protective antibody response to apical membrane antigen 1 | Q34007362 |
| | Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine | Q34011922 |
| | Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial | Q34043843 |
| | Targeting sialic acid dependent and independent pathways of invasion in Plasmodium falciparum | Q34131196 |
| | Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+T cells targeting AMA1 class I epitopes | Q34165879 |
| | Safety and immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 Region II malaria vaccine in healthy adults living in an area where malaria is not endemic | Q34189972 |
| | A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a malaria vaccine candidate | Q34232909 |
| | The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody | Q34241973 |
| | Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure | Q34257253 |
| | In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response | Q34260615 |
| | Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria | Q34260722 |
| | Malaria vaccine R&D in the Decade of Vaccines: breakthroughs, challenges and opportunities | Q34340186 |
| | Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle | Q34341570 |
| | T cell responses induced by adenoviral vectored vaccines can be adjuvanted by fusion of antigen to the oligomerization domain of C4b-binding protein | Q34416263 |
| | Limited antigenic diversity of Plasmodium falciparum apical membrane antigen 1 supports the development of effective multi-allele vaccines | Q34416904 |
| | Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria | Q34441098 |
| | Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51 | Q34546201 |
| | Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum. | Q34548828 |
| | Use of immunodampening to overcome diversity in the malarial vaccine candidate apical membrane antigen 1. | Q34596157 |
| | Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial | Q34600955 |
| | DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity | Q34606356 |
| | Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection | Q34687174 |
| | A longitudinal study of immune responses to Plasmodium falciparum sexual stage antigens in Tanzanian adults | Q43945792 |
| | Expression of malaria transmission-blocking vaccine antigen Pfs25 in Pichia pastoris for use in human clinical trials | Q44150427 |
| | Experimental human challenge infections can accelerate clinical malaria vaccine development | Q44156054 |
| | Antibodies to plant-produced Plasmodium falciparum sexual stage protein Pfs25 exhibit transmission blocking activity | Q44156482 |
| | A comparison of transmission-blocking activity with reactivity in a Plasmodium falciparum 48/45-kD molecule-specific competition enzyme-linked immunosorbent assay. | Q44169960 |
| | The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from malaria endemic and non-endemic areas | Q44238175 |
| | Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea | Q44501476 |
| | Enzymic, phylogenetic, and structural characterization of the unusual papain-like protease domain of Plasmodium falciparum SERA5. | Q44588572 |
| | Fc gamma receptor 3B (FCGR3B-c.233C>A-rs5030738) polymorphism modifies the protective effect of malaria specific antibodies in ghanaian children | Q45172424 |
| | Naturally acquired antibodies to the glutamate-rich protein are associated with protection against plasmodium falciparum malaria | Q46163143 |
| | A hypothesis about the chronicity of malaria infection | Q46833996 |
| | Ca(2+) -mediated exocytosis of subtilisin-like protease 1: a key step in egress of Plasmodium falciparum merozoites | Q46908547 |
| | Complement-mediated killing of Plasmodium falciparum erythrocytic schizont with antibodies to the recombinant serine repeat antigen (SERA). | Q47773289 |
| | Conservation and heterogeneity of the glutamate-rich protein (GLURP) among field isolates and laboratory lines of Plasmodium falciparum | Q47812641 |
| | Epitope analysis of the malaria surface antigen pfs48/45 identifies a subdomain that elicits transmission blocking antibodies. | Q47829675 |
| | Immunological properties of recombinant proteins of the transmission blocking vaccine candidate, Pfs48/45, of the human malaria parasite Plasmodium falciparum produced in Escherichia coli. | Q47837358 |
| | Assembly and expression of a synthetic gene encoding the antigen Pfs48/45 of the human malaria parasite Plasmodium falciparum in yeast | Q47857505 |
| | Allelic polymorphisms in apical membrane antigen-1 are responsible for evasion of antibody-mediated inhibition in Plasmodium falciparum | Q47864459 |
| | Synthetic peptides derived from the C-terminal 6kDa region of Plasmodium falciparum SERA5 inhibit the enzyme activity and malaria parasite development | Q47864896 |
| | Malaria vaccine candidate antigen targeting the pre-erythrocytic stage of Plasmodium falciparum produced at high level in plants | Q47882452 |
| | Reticulocyte-binding protein homologue 5 - an essential adhesin involved in invasion of human erythrocytes by Plasmodium falciparum | Q47887452 |
| | Vaccinating with the genome: a Sisyphean task? | Q47899824 |
| | Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium. | Q47928079 |
| | Immunogenicity and in vitro protective efficacy of recombinant Mycobacterium bovis bacille Calmette Guerin (rBCG) expressing the 19 kDa merozoite surface protein-1 (MSP-119) antigen of Plasmodium falciparum | Q47964774 |
| | Production of non-glycosylated recombinant proteins in Nicotiana benthamiana plants by co-expressing bacterial PNGase F. | Q48007592 |
| | Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes | Q48013154 |
| | The high immunogenicity induced by modified sporozoites' malarial peptides depends on their phi (ϕ) and psi (ψ) angles | Q48025225 |
| | Heterologous expression of proteins from Plasmodium falciparum: results from 1000 genes | Q48028328 |
| | Diversity of the vaccine candidate AMA-1 of Plasmodium falciparum | Q48065126 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 52 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | malaria | Q12156 |
| | malaria vaccine | Q6741353 |
| | recombinant protein | Q50209538 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 7433-7443 | |
| P577 | publication date | 2015-10-09 | |
| | 2015-12-22 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Recent advances in recombinant protein-based malaria vaccines | |
| P478 | volume | 33 | |